General Information
    • ISSN: 2010-0264
    • Frequency: Bimonthly (2010-2014); Monthly (Since 2015)
    • DOI: 10.18178/IJESD
    • Editor-in-Chief: Prof. Richard Haynes
    • Executive Editor: Ms. Nancy Y. Liu
    • Abstracting/ Indexing: Chemical Abstracts Services (CAS), CABI, DOAJ, Ulrich Periodicals Directory, Engineering & Technology Digital Library, Electronic Journals Library, Crossref, ProQuest.
    • E-mail: ijesd@ejournal.net
  • May 04, 2017 News! Vol. 8, No. 7 has been indexed by Crossref.
  • May 02, 2017 News! Vol.8, No.7 has been published with online version!   [Click]
Editor-in-chief
The University of Queensland, Australia
It is my honor to be the editor-in-chief of IJESD. The journal publishes good papers in the field of environmental science and development.
IJESD 2012 Vol.3(3): 274-278 ISSN: 2010-0264
DOI: 10.7763/IJESD.2012.V3.230

Influence of ABCB1 C3435T and ABCG2 C421A Gene Polymorphisms in Response to Imatinib Mesylatein Chronic Myeloid Leukemia Patients

A. Anthony, R. Ankathil, G. Ai-Sim, S. A. W. Fadilah, and A. A. Baba

Abstract—Despite the excellent efficacy results of IM treatment in CML patients, resistance to IM has emerged as a significant problem. Genetic variations in genes involved in drug transportation encoding membrane transporters such as ABCB1 and ABCG2 might influence the pharmacokinetic and metabolism of IM. The genotype of a patient is increasingly recognized in influencing the response to the treatment. In this study, the relationship between IM response and 2 SNPs (ABCB1 C3435T and ABCG2 C421A) were investigated among Malaysian CML patients undergoing IM treatment. Peripheral blood was withdrawn from 91 healthy individuals and 45 CML patients undergoing IM treatment. DNA was extracted from the blood samples and followed by the genotyping technique using PCR-RFLP method. The results showed the homozygous wild type genotype (CC) of SNP ABCB1 C3435T was higher in CML patients showing IM resistant compared to IM good response CML patients with p = 0.004. Interestingly, IM resistance was lower for patients homozygous for the A allele of ABCG2 SNP C421A compared to patients with C allele (33% vs. 64%, p=0.0001). Besides, these 2 SNPs were found not to contribute to the genetic susceptibility of CML when evaluated with healthy control subjects. These preliminary results prompt us to suggest the possibility of exploring these SNPs as biomarkers to predict the response to IM in CML patients prior to IM treatment.

Index Terms—ABCB1 C3435T, ABCG2 C421A, polymorphisms, imatinib mesylate, chronic myeloid leukemia(CML).

A. Au and R. Ankathil are with the Human Genome Centre, School of Medical Sciences, Universiti Sains Malaysia, Malaysia. (email: auzl@live.com; rankathil@hotmail.com)
A. S. Goh is with Hospital Pulau Pinang, Malaysia.
F. S. A. Wahid is with the Cell Therapy Centre, UKM Medical Centre, Universiti Kebangsaan Malaysia, Malaysia.
A. A. Baba is the Dean, School of Medical Sciences, Universiti Sains Malaysia, Malaysia (email: ababa@kb.usm.my)

[PDF]

Cite: A. Anthony, R. Ankathil, G. Ai-Sim, S. A. W. Fadilah, and A. A. Baba, "Influence of ABCB1 C3435T and ABCG2 C421A Gene Polymorphisms in Response to Imatinib Mesylatein Chronic Myeloid Leukemia Patients," International Journal of Environmental Science and Development vol. 3, no. 3, pp. 274-278, 2012.

Copyright © 2008-2017. International Journal of Environmental Science and Development. All rights reserved.
E-mail: ijesd@ejournal.net